Nakeda Hall
Nurse Practitioner · Lawton, OKNPI 1700226040
Payments from drug & device makers
Across 102 payments — averaging $18.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$309
- AstraZeneca$278
- GSK$247
- Pfizer$245
- Scynexis, Inc.$117
- AbbVie$107
- plus $611 from 18 others
What the payments were for
- Food & beverage$1,914100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 17 | $309 |
| AstraZeneca | 16 | $278 |
| GSK | 14 | $247 |
| Pfizer | 14 | $245 |
| Scynexis, Inc. | 1 | $117 |
| AbbVie | 5 | $107 |
| Sage Therapeutics, LLC | 4 | $76 |
| Supernus Pharmaceuticals, Inc. | 3 | $54 |
| Sanofi-aventis U.S. LLC | 3 | $49 |
| Boehringer Ingelheim | 3 | $47 |
| Astellas Pharma US Inc | 2 | $45 |
| Merck | 3 | $44 |
| Exact Sciences | 3 | $44 |
| Organon | 3 | $43 |
| Amgen | 2 | $35 |
| Novo Nordisk | 1 | $26 |
| Mylan Specialty L.p. | 1 | $25 |
| Sanofi | 1 | $24 |
| Teva Pharmaceuticals USA, Inc. | 1 | $20 |
| Tactile Systems Technology Inc | 1 | $19 |
| Viatris Specialty LLC | 1 | $18 |
| Lundbeck LLC | 1 | $16 |
| Dexcom, Inc. | 1 | $14 |
| E.r. Squibb & Sons, L.L.C. | 1 | $12 |
How this compares
$1,914 in reported general payments places this provider in the 85th percentile of 824 nurse practitioner providers in Oklahoma.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 59 | $57,965 |
| MounjaroTirzepatide | 30 | $30,388 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 40 | $30,068 |
| EliquisApixaban | 39 | $29,562 |
| TrulicityDulaglutide | 24 | $22,549 |
| Victoza 3-PakLiraglutide | 16 | $20,949 |
| OzempicSemaglutide | 14 | $17,664 |
| SymbicortBudesonide/Formoterol Fumarate | 28 | $9,201 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 48 | $5,690 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 97 | $3,091 |
| Tolterodine Tartrate ErTolterodine Tartrate | 11 | $2,535 |
| Atorvastatin Calcium | 120 | $1,412 |
| Losartan Potassium | 121 | $1,042 |
| Gabapentin | 116 | $1,014 |
| Amlodipine Besylate | 148 | $927 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $47 | $57,96559 claims |
| Lilly USA, LLCMounjaro, Trulicity | $309 | $52,93754 claims |
| GSKTrelegy Ellipta | $247 | $30,06840 claims |
| PfizerEliquis | $245 | $29,56239 claims |
| Novo NordiskOzempic | $26 | $17,66414 claims |
| AstraZenecaSymbicort | $278 | $9,20128 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 824 nurse practitioner providers in Oklahoma.
Other nurse practitioner in Lawton
- Jenny GuthrieTulsa$106K
- Leah MeltonNorman$87K
- Sara GoreOklahoma City$52K
- Teisha GalleglyMoore$43K
- Stacy NewberryTulsa$28K
- Russell RoomsOklahoma City$24K
- Grant YoungOklahoma City$15K
- Monica LawsonNorman$15K
- Amanda SmallTulsa$14K
- Janelle WagnerOklahoma City$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.